BÜHLMANN IBDoc® Assay Citations Archives | Buhlmann Diagnostics Corp

Category: BÜHLMANN IBDoc® Assay Citations

US: BÜHLMANN IBDoc® is Not Available for Sale.
Canada: Health Canada Licence: 98903, Device class: 3
Canadian customers: A number of the publications in the citation list describe applications that are outside of product claims (Intended Use: IBDoc® is intended as an aid to the determination of the inflammatory status of the patient’s intestinal mucosa for inflammatory bowel disease (e.g. Crohn’s Disease and Ulcerative Colitis) monitoring.) thus they should be used for information only.

Smartphone-based Health Applications IBDsmart and Doc®

McCombie A. et al., A non-inferiority randomized clinical trial of the use of the smartphone-based health applications IBDsmart and Doc® in the care of IBD patients, Inflamm Bowel Dis, 2019 Highlights from this Publication "Remote symptom and fecal calprotectin monitoring is effective and acceptable. It also reduces the need for face-to-face outpatient appointments." Read Citation
Continue Reading

fecal Calprotectin as a Substitute for Routine Laboratory Analysis

Hejl et al.; Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis. Practical Laboratory Medicine, 2017 Highlights from this Publication "This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients." Read Citation Health Canada License: 98903 US: Not available for sale in
Continue Reading

Usability of a Home-based Test for the Measurement of fecal Calprotectin

Bello C. et al., Usability of a home-based test for the measurement of fecal calprotectin in asymptomatic IBD patients, Digestive and Liver Disease, 2017 Highlights from this Publication "The adherence to home-based measurement of FC was fair. Usability scores for the home-based test were high. There was a good correlation with the centrally measured FC
Continue Reading

Home-based Measurement of Stool Calprotectin and ELISA Results

Heida A. et al., Agreement Between Home-based Measurement of Stool Calprotectin and ELISA Results for Monitoring Inflammatory Bowel Disease Activity, Clin Gastroenterology and Hepatology, 2017 Highlights from this Publication "Measurements of fecal levels of calprotectin made with home-based lateral flow method were in agreement with measurements made by Quantum Blue and ELISA, as long as
Continue Reading

ECCO 2020 Poster – IBDoc Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH)

IBDoc® Citation: Avery, P. et. al. N05: IBDoc® Faecal calprotectin self-test retrospective audit in a District General Hospital (DGH).  ECCO 2020, Feb 12-15. Highlights from this Publication “ …This data also helps separate well from unwell patients, offering further opportunities to promote supported self-management in people with IBD and prioritisation of clinic appointments....” Read Citation Health
Continue Reading

ECCO 2020 Poster: IBD Home at GHP Stockholm Gastro Center in Sweden

IBDoc® Citation: S. Jäghult et. al.  N08: IBD Home at GHP Stockholm Gastro Center in Sweden. ECCO 2020, Feb 12-15. Highlights from this Publication “ …The majority (n = 24) stated that it was easy to install IBD Home. A total of nine patients noted that their participation in their own health care had increased...” “
Continue Reading

ECCO 2020 Poster – An evaluation of the impact of IBDoc

BÜHLMANN IBDoc®: Sugrue, K. et al.  N12: An evaluation of the impact of IBDoc in clinical practice 5 years after introduction.  ECCO 2020, Feb 12 – 15, 2020. Vienna, Austria. Highlights from this Publication “This study shows the benefits of using IBDoc® in clinical practice. It is central to facilitating a fast track system for patients
Continue Reading

IBDoc Key Literature List

IBDoc® Publications View a compilation of BÜHLMANN IBDoc® calprotectin citations from a wide variety of interesting publications, studies, and posters. Find valuable highlights from each publication and see the long list of studies that have utilized our assay!   View Citations Health Canada License: 98903 US: Not available for Sale in the US.
Continue Reading

Clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc

IBDoc® Citation: ECCO 2019 Poster Walmsley et al. Poster: P630 A non-inferiority randomised clinical trial of the use of the smartphone-based health applications IBDsmart and IBDoc® in the care of inflammatory bowel disease patients. ECCO 2019: Inflammatory Bowel Diseases 14th Congress, March 6-9, 2019, Copenhagen/Denmark. Highlights from this Poster   “Use of IBDsmart and IBDoc® in
Continue Reading

Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease

BÜHLMANN IBDoc®: Orfanourdaki et al. The Real World Use of Fecal Calprotectin Home Testing in Patients with Inflammatory Bowel Disease Under Maintenance Treatment with Adalimumab.  UEGW 2019, Feb 09 – 11, 2018. Barcelona, Spain. P1074 Read Citation Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is Not Available for Sale in the US.
Continue Reading